Regulatory approval

Published by the Health Service Executive. Withdrawn

Relapsed or refractory CD20 positive diffuse large B cell lymphoma in patients ineligible for stem cell transplant.

This is written in the approval document.

Reimbursement

N/A

Citation

R-Gemcitabine (1000mg/m2) Oxaliplatin Therapy - 14 day, 2025, version number 5, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/6510/506_v4_R-Gem_OX.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2018-08-13	Health Service Executive	Indication approved for reimbursement.